webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

N3-L-Cit-OH

  CAS No.: 1799421-66-1   Cat No.: BADC-01789   Purity: >98% 4.5  

N3-L-Cit-OH is an ADC linker building block incorporating an azide group and cleavable citrulline moiety, enabling selective intracellular drug release. It supports the design of highly effective antibody-drug conjugates with improved stability and payload delivery. Key terms: ADC linker, cleavable linker, azide functional group, payload release.

N3-L-Cit-OH

Structure of 1799421-66-1

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C6H11N5O3
Molecular Weight
201.19
Shipping
Store at 2-8 °C

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
N3-L-Cit-OH dicyclohexylamine; N3-Cit-OH; N3-Cit; (S)-2-Azido-citrulline; Azido-citrulline; (2S)-5-[(Aminocarbonyl)amino]-2-azidopentanoic acid
IUPAC Name
(2S)-2-azido-5-(carbamoylamino)pentanoic acid
Canonical SMILES
C(C[C@@H](C(=O)O)N=[N+]=[N-])CNC(=O)N
InChI
InChI=1S/C6H11N5O3/c7-6(14)9-3-1-2-4(5(12)13)10-11-8/h4H,1-3H2,(H,12,13)(H3,7,9,14)/t4-/m0/s1
InChIKey
WTCIIDRGWZAPDA-BYPYZUCNSA-N
Storage
Store at 2-8 °C

N3-L-Cit-OH is a key intermediate in peptide synthesis, particularly for incorporating citrulline, a non-proteinogenic amino acid, into peptides. Citrulline plays a vital role in various biological processes, such as nitric oxide synthesis, and the incorporation of N3-L-Cit-OH into peptides can impart unique biological functions. The N3-protection group ensures controlled deprotection during synthesis, making N3-L-Cit-OH a versatile building block for designing peptides with enhanced stability, selectivity, and bioactivity.

One of the primary applications of N3-L-Cit-OH is in the development of peptides that target specific biological pathways, especially in areas related to cardiovascular health and immune modulation. Citrulline, through its role in nitric oxide production, can influence vascular tone and blood flow. By incorporating N3-L-Cit-OH into therapeutic peptides, researchers can create peptide-based drugs that may help manage conditions such as hypertension, erectile dysfunction, and other vascular diseases. These peptides can provide a targeted, effective alternative to traditional drug therapies.

Another important application of N3-L-Cit-OH is in the synthesis of modified peptides for drug delivery systems. The incorporation of citrulline can enhance the solubility, stability, and pharmacokinetic properties of peptides. N3-L-Cit-OH can be used to create peptides that are more resistant to enzymatic degradation, making them more effective as drug candidates. Additionally, citrulline-containing peptides can be conjugated to drugs or other bioactive molecules to improve their targeting ability and reduce systemic toxicity, thus improving the efficacy and safety profiles of therapeutic agents.

N3-L-Cit-OH is also utilized in the creation of peptide-based vaccines and therapeutic agents. Citrulline, due to its role in immune modulation and its ability to alter protein folding, is an attractive target for developing peptides that can interact with immune cells. The incorporation of N3-L-Cit-OH into peptide vaccines could enhance immune system activation and provide a more robust immune response. This has potential applications in the development of vaccines for autoimmune diseases, cancer immunotherapy, and other conditions requiring immune system modulation.

Furthermore, N3-L-Cit-OH is valuable in the design of cyclic peptides and peptide mimetics. The incorporation of citrulline allows for greater flexibility in peptide structure, facilitating the formation of cyclic peptides that are more stable and resistant to proteolysis. These cyclic peptides are crucial in drug discovery as they can target specific proteins, enzymes, or receptors with higher specificity and affinity, which is especially useful in oncology, neurodegenerative diseases, and infectious diseases.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Daunorubicin citrate | N3-L-Val-OH (CHA) | N3-L-Cys(Trt)-OH CHA | N3-L-Leu-OH | N3-L-Lys(Mtt)-OH | N3-L-Orn(Fmoc)-OH | N3-L-Dab(Fmoc)-OH | N3-L-Cit-OH
Send Inquiry
Verification code
Inquiry Basket